Prostate cancer vaccines, including dendritic and peptide types, offer hope for improved treatments, but face hurdles in ...

Delve into the expanding and diverse field of cancer vaccines with various approaches exploiting the immune system to fight ...

Interesting targets for peptide vaccination have been defined including Wilms tumor gene 1 ... For the three aforementioned antigens, more and more epitope peptides have been defined.

Cancer treatment has entered a revolutionary phase with advancements in immunotherapy, a field that employs the immune system ...

Data from the ongoing Phase 2 of EO4010 demonstrate tumor target specific immune responses and objective tumor responses, including in liver ...

These peptides (T-cell epitopes ... Focusing on a limited set of antigens is also relevant to cancer vaccination in which tumour cells or lysates may contain predominantly normal self-proteins ...

Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated ...

Receptors are cellular components that trigger internal changes based on external signals. Researchers have built a new synthetic receptor with incredibly broad potential to program cell activity, ...

Such HSP-peptide complexes are actively taken up by APCs and are able to stimulate antigen-specific T-cell ... the demonstration that these can induce tumor-specific T-cell responses.

CNW/ -- (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the Company") presented a new study today at the Personalized ...

Cancer cells impair monocyte-mediated T-cell activation by disrupting inflammatory pathways in the tumor microenvironment.

CLSP-1025 is a half-life extended TCE targeting cancer cells expressing the ... can selectively bind HLA (human leukocyte antigen)-presented peptides derived from these oncogenic drivers.